Physician profile
Jeffrey Hill
NPI 1073826962
$3,723.57
in general payments reported to CMS, 2019-2025
21 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.90 · 2022: $104 · 2023: $1,029 · 2024: $848 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $780.31 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $615.23 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $490.28 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $310.33 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $281.04 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $152.09 | 2023-2024 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $151.15 | 2023-2025 | Ingrezza |
| Amgen INC. | $128.91 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $126.64 | 2025 | Wainua |
| Supernus Pharmaceuticals, INC. | $117.15 | 2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $117.00 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $108.81 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $98.94 | 2025 | Cobenfy |
| Corium, LLC | $58.66 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $43.69 | 2021-2023 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.98 | 2022-2023 | |
| Noven Therapeutics, LLC | $32.14 | 2023 | Xelstrym, Secuado |
| Boston Scientific Corporation | $22.14 | 2025 | Wavewriter Alpha Prime 16 |
| Chiesi USA, INC. | $21.45 | 2022 | |
| Acadia Pharmaceuticals INC | $15.51 | 2023 | Nuplazid |
| Neos Therapeutics, LP | $13.12 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.